{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:56:16Z","timestamp":1781762176341,"version":"3.54.5"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02133-3","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:10:06Z","timestamp":1775135406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TIM-3 in AML: pathogenic roles and therapeutic targetability"],"prefix":"10.1007","volume":"26","author":[{"given":"Liyan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"5853","key":"2133_CR1","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1148536","volume":"318","author":"AC Anderson","year":"2007","unstructured":"Anderson AC, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141\u20133.","journal-title":"Science"},{"issue":"1","key":"2133_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","volume":"33","author":"M de Pulido","year":"2018","unstructured":"de Pulido M. TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 2018;33(1):60\u201374. .e6.","journal-title":"Cancer Cell"},{"issue":"13","key":"2133_CR3","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","volume":"119","author":"MK Gleason","year":"2012","unstructured":"Gleason MK, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012;119(13):3064\u201372.","journal-title":"Blood"},{"issue":"1","key":"2133_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24(1):5.","journal-title":"Mol Cancer"},{"issue":"16","key":"2133_CR5","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","volume":"119","author":"LC Ndhlovu","year":"2012","unstructured":"Ndhlovu LC, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119(16):3734\u201343.","journal-title":"Blood"},{"issue":"1","key":"2133_CR6","doi-asserted-by":"publisher","first-page":"1889822","DOI":"10.1080\/2162402X.2021.1889822","volume":"10","author":"J Rakova","year":"2021","unstructured":"Rakova J, et al. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. Oncoimmunology. 2021;10(1):1889822.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2133_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, et al. A TIM-3\/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. Cell Stem Cell. 2015;17(3):341\u201352.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"2133_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708\u201317.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2133_CR9","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024;11(1):e38\u201350.","journal-title":"Lancet Haematol"},{"issue":"2","key":"2133_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.","journal-title":"Blood Cancer J"},{"issue":"5","key":"2133_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bulcan.2018.01.018","volume":"105","author":"F Liu","year":"2018","unstructured":"Liu F, et al. Blocking Tim-3 or\/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma. Bull Cancer. 2018;105(5):493\u2013501.","journal-title":"Bull Cancer"},{"issue":"4","key":"2133_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","volume":"153","author":"G Zhou","year":"2017","unstructured":"Zhou G, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153(4):1107\u201319. e10.","journal-title":"Gastroenterology"},{"key":"2133_CR13","doi-asserted-by":"crossref","unstructured":"Abaza Y, Zeidan AM. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cells, 2022. 11(14). p.2249","DOI":"10.3390\/cells11142249"},{"issue":"W1","key":"2133_CR14","doi-asserted-by":"publisher","first-page":"W520","DOI":"10.1093\/nar\/gkad408","volume":"51","author":"F-C Qian","year":"2023","unstructured":"Qian F-C, et al. SEanalysis 2.0: a comprehensive super-enhancer regulatory network analysis tool for human and mouse. Nucleic Acids Res. 2023;51(W1):W520\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2133_CR15","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A. 2011;108(12):5009\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2133_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/imm.12665","volume":"149","author":"D Ozkazanc","year":"2016","unstructured":"Ozkazanc D, et al. Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells. Immunology. 2016;149(4):460\u201371.","journal-title":"Immunology"},{"issue":"8","key":"2133_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/jim-2019-001059","volume":"67","author":"R Fu","year":"2019","unstructured":"Fu R, et al. Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome. J Investig Med. 2019;67(8):1125\u201330.","journal-title":"J Investig Med"},{"key":"2133_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.leukres.2016.11.003","volume":"51","author":"J Tao","year":"2016","unstructured":"Tao J, et al. Increased TIM3\u2009+\u2009CD8+T cells in Myelodysplastic Syndrome patients displayed less perforin and granzyme B secretion and higher CD95 expression. Leuk Res. 2016;51:49\u201355.","journal-title":"Leuk Res"},{"issue":"51","key":"2133_CR19","doi-asserted-by":"publisher","first-page":"88904","DOI":"10.18632\/oncotarget.21492","volume":"8","author":"T Asayama","year":"2017","unstructured":"Asayama T, et al. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget. 2017;8(51):88904\u201317.","journal-title":"Oncotarget"},{"issue":"32","key":"2133_CR20","doi-asserted-by":"publisher","first-page":"33823","DOI":"10.18632\/oncotarget.5257","volume":"6","author":"I Gon\u00e7alves Silva","year":"2015","unstructured":"Gon\u00e7alves Silva I, et al. Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells. Oncotarget. 2015;6(32):33823\u201333.","journal-title":"Oncotarget"},{"issue":"10","key":"2133_CR21","first-page":"6880","volume":"7","author":"C Li","year":"2014","unstructured":"Li C, et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. Int J Clin Exp Pathol. 2014;7(10):6880\u20138.","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"2133_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.b.21080","volume":"84","author":"CG Roth","year":"2013","unstructured":"Roth CG, et al. TIM3 expression by leukemic and non-leukemic myeloblasts. Cytometry B Clin Cytom. 2013;84(3):167\u201372.","journal-title":"Cytometry B Clin Cytom"},{"key":"2133_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/jrms.JRMS_759_19","volume":"25","author":"NZ Balajam","year":"2020","unstructured":"Balajam NZ, et al. Study of T-cell immunoglobulin and mucin domain-3 expression profile in peripheral blood and bone marrow of human acute lymphoblastic leukemia patients. J Res Med Sci. 2020;25:69.","journal-title":"J Res Med Sci"},{"key":"2133_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clim.2018.02.009","volume":"190","author":"L Liu","year":"2018","unstructured":"Liu L, et al. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clin Immunol. 2018;190:32\u201340.","journal-title":"Clin Immunol"},{"issue":"4","key":"2133_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000497208","volume":"42","author":"L Hadadi","year":"2019","unstructured":"Hadadi L, et al. Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. Oncol Res Treat. 2019;42(4):202\u20138.","journal-title":"Oncol Res Treat"},{"issue":"7","key":"2133_CR26","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","volume":"32","author":"O Br\u00fcck","year":"2018","unstructured":"Br\u00fcck O, et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 2018;32(7):1643\u201356.","journal-title":"Leukemia"},{"key":"2133_CR27","doi-asserted-by":"crossref","unstructured":"Rezaei M et al. TIM-3 in Leukemia; Immune Response and Beyond. Front Oncol, 2021. Volume 11\u20132021.","DOI":"10.3389\/fonc.2021.753677"},{"key":"2133_CR28","doi-asserted-by":"crossref","unstructured":"Wang Z, et al. One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia. Frontiers in Immunology; 2021. pp. 12\u20132021.","DOI":"10.3389\/fimmu.2021.618710"},{"issue":"3","key":"2133_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173\u201385.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2133_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/ejh.ejh_24_23","volume":"49","author":"HM Atif","year":"2024","unstructured":"Atif HM, Eid IAM. A T-cell receptor as a promising immunotherapeutic target in acute myeloid leukemia: expression of T cell immunoglobulin and mucin-containing-3 on bone marrow hematopoietic cells. Egypt J Haematol. 2024;49(1):83\u201391.","journal-title":"Egypt J Haematol"},{"issue":"7","key":"2133_CR31","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1002\/cam4.5549","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, et al. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia. Cancer Med. 2023;12(7):8956\u201369.","journal-title":"Cancer Med"},{"issue":"6871","key":"2133_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536\u201341.","journal-title":"Nature"},{"issue":"12","key":"2133_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/ni739","volume":"2","author":"JJ McIntire","year":"2001","unstructured":"McIntire JJ, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 2001;2(12):1109\u201316.","journal-title":"Nat Immunol"},{"issue":"7969","key":"2133_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","volume":"619","author":"L Bod","year":"2023","unstructured":"Bod L, et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature. 2023;619(7969):348\u201356.","journal-title":"Nature"},{"issue":"12","key":"2133_CR35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352.","journal-title":"Nat Immunol"},{"issue":"1","key":"2133_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clim.2012.01.004","volume":"143","author":"S Oomizu","year":"2012","unstructured":"Oomizu S, et al. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin Immunol. 2012;143(1):51\u20138.","journal-title":"Clin Immunol"},{"issue":"1","key":"2133_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","volume":"127","author":"M Seki","year":"2008","unstructured":"Seki M, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127(1):78\u201388.","journal-title":"Clin Immunol"},{"issue":"3","key":"2133_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/ijms18030645","volume":"18","author":"W Du","year":"2017","unstructured":"Du W, et al. TIM-3 as a target for cancer immunotherapy and mechanisms of action. Int J Mol Sci. 2017;18(3):645.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2133_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.immuni.2007.01.016","volume":"26","author":"E Cao","year":"2007","unstructured":"Cao E, et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 2007;26(3):311\u201321.","journal-title":"Immunity"},{"issue":"16","key":"2133_CR40","first-page":"3821","volume":"113","author":"M Nakayama","year":"2009","unstructured":"Nakayama M, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. J Am Soc Hematol. 2009;113(16):3821\u201330.","journal-title":"J Am Soc Hematol"},{"issue":"2","key":"2133_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"9","key":"2133_CR42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832\u201342.","journal-title":"Nat Immunol"},{"issue":"9","key":"2133_CR43","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1111\/cas.15042","volume":"112","author":"Y Kikushige","year":"2021","unstructured":"Kikushige Y. TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways. Cancer Sci. 2021;112(9):3419\u201326.","journal-title":"Cancer Sci"},{"issue":"7534","key":"2133_CR44","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature13848","volume":"517","author":"YH Huang","year":"2015","unstructured":"Huang YH, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386\u201390.","journal-title":"Nature"},{"issue":"2","key":"2133_CR45","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4049\/jimmunol.1302663","volume":"192","author":"KL Clayton","year":"2014","unstructured":"Clayton KL, et al. T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol. 2014;192(2):782\u201391.","journal-title":"J Immunol"},{"issue":"9","key":"2133_CR46","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","volume":"18","author":"M Rangachari","year":"2012","unstructured":"Rangachari M, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion. Nat Med. 2012;18(9):1394\u2013400.","journal-title":"Nat Med"},{"issue":"19","key":"2133_CR47","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/MCB.05297-11","volume":"31","author":"J Lee","year":"2011","unstructured":"Lee J, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31(19):3963\u201374.","journal-title":"Mol Cell Biol"},{"key":"2133_CR48","doi-asserted-by":"publisher","first-page":"p117225","DOI":"10.1016\/j.biopha.2024.117225","volume":"178","author":"F Li","year":"2024","unstructured":"Li F, et al. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1). Biomed Pharmacother. 2024;178:p117225.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2133_CR49","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/bloodadvances.2022008405","volume":"7","author":"T Sakoda","year":"2023","unstructured":"Sakoda T, et al. TIM-3 signaling hijacks the canonical Wnt\/beta-catenin pathway to maintain cancer stemness in acute myeloid leukemia. Blood Adv. 2023;7(10):2053\u201365.","journal-title":"Blood Adv"},{"issue":"10","key":"2133_CR50","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187\u201394.","journal-title":"J Exp Med"},{"issue":"17","key":"2133_CR51","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, et al. Coexpression of Tim-3 and PD-1 identifies a CD8\u2009+\u2009T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501\u201310.","journal-title":"Blood"},{"issue":"7","key":"2133_CR52","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Y Kong","year":"2015","unstructured":"Kong Y, et al. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015;5(7):e330.","journal-title":"Blood Cancer J"},{"key":"2133_CR53","doi-asserted-by":"publisher","first-page":"106122","DOI":"10.1016\/j.intimp.2019.106122","volume":"80","author":"K Wu","year":"2020","unstructured":"Wu K, et al. V\u03b42 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. Int Immunopharmacol. 2020;80:106122.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2133_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.imbio.2019.03.001","volume":"224","author":"EC So","year":"2019","unstructured":"So EC, et al. NK cell expression of Tim-3: First impressions matter. Immunobiology. 2019;224(3):362\u201370.","journal-title":"Immunobiology"},{"issue":"1","key":"2133_CR55","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jcmm.14825","volume":"24","author":"J Tao","year":"2020","unstructured":"Tao J, et al. CD8(+) T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3\/Gal-9 pathway. J Cell Mol Med. 2020;24(1):1046\u201358.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2133_CR56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/imm.13488","volume":"168","author":"S Yu","year":"2023","unstructured":"Yu S, et al. TIM3\/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8(+) T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome. Immunology. 2023;168(2):273\u201389.","journal-title":"Immunology"},{"key":"2133_CR57","doi-asserted-by":"crossref","unstructured":"Duan W-W, et al. A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. Volume 30. CNS Neuroscience & Therapeutics; 2024. p. e14489. 4.","DOI":"10.1111\/cns.14489"},{"issue":"1","key":"2133_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","volume":"7","author":"P Dama","year":"2019","unstructured":"Dama P, et al. Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7(1):175.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2133_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64\u201374.","journal-title":"Leukemia"},{"issue":"3","key":"2133_CR60","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/leu.2011.387","volume":"26","author":"TC Luis","year":"2012","unstructured":"Luis TC, et al. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia. 2012;26(3):414\u201321.","journal-title":"Leukemia"},{"issue":"4","key":"2133_CR61","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/JLB.2MR0420-707R","volume":"108","author":"SC Soares-Lima","year":"2020","unstructured":"Soares-Lima SC, Pombo-de-Oliveira MS, Carneiro FRG. The multiple ways Wnt signaling contributes to acute leukemia pathogenesis. J Leukoc Biol. 2020;108(4):1081\u201399.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"2133_CR62","doi-asserted-by":"publisher","first-page":"e1195535","DOI":"10.1080\/2162402X.2016.1195535","volume":"5","author":"I Gon\u00e7alves Silva","year":"2016","unstructured":"Gon\u00e7alves Silva I, et al. The immune receptor Tim-3 acts as a trafficker in a Tim-3\/galectin-9 autocrine loop in human myeloid leukemia cells. Oncoimmunology. 2016;5(7):e1195535.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2133_CR63","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cas.16431","volume":"116","author":"T Sakoda","year":"2025","unstructured":"Sakoda T, et al. TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation. Cancer Sci. 2025;116(3):698\u2013709.","journal-title":"Cancer Sci"},{"key":"2133_CR64","doi-asserted-by":"publisher","first-page":"879471","DOI":"10.3389\/fonc.2022.879471","volume":"12","author":"J Hong","year":"2022","unstructured":"Hong J, et al. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes. Front Oncol. 2022;12:879471.","journal-title":"Front Oncol"},{"issue":"60","key":"2133_CR65","doi-asserted-by":"publisher","first-page":"102088","DOI":"10.18632\/oncotarget.22141","volume":"8","author":"L Xu","year":"2017","unstructured":"Xu L, et al. High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity. Oncotarget. 2017;8(60):102088\u201396.","journal-title":"Oncotarget"},{"issue":"1","key":"2133_CR66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1089\/bio.2017.0079","volume":"16","author":"EL Pogosova-Agadjanyan","year":"2018","unstructured":"Pogosova-Agadjanyan EL, et al. Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. Biopreserv Biobank. 2018;16(1):42\u201352.","journal-title":"Biopreserv Biobank"},{"issue":"5","key":"2133_CR67","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1177\/0300985820960132","volume":"58","author":"JD Webster","year":"2020","unstructured":"Webster JD, Solon M, Gibson-Corley KN. Validating Immunohistochemistry Assay Specificity in Investigative Studies: Considerations for a Weight of Evidence Approach. Vet Pathol. 2020;58(5):829\u201340.","journal-title":"Vet Pathol"},{"key":"2133_CR68","doi-asserted-by":"crossref","unstructured":"Desai RH, Zandvakili N, Bohlander SK. Dissecting the Genetic and Non-Genetic Heterogeneity of Acute Myeloid Leukemia Using Next-Generation Sequencing and In Vivo Models. Cancers (Basel), 2022. 14(9). p.2182","DOI":"10.3390\/cancers14092182"},{"key":"2133_CR69","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","volume":"4","author":"GV Masucci","year":"2016","unstructured":"Masucci GV, et al. Validation of biomarkers to predict response to immunotherapy in cancer: I - pre-analytical and analytical validation. J Immunother Cancer. 2016;4:76.","journal-title":"J Immunother Cancer"},{"key":"2133_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2023-180876","volume":"142","author":"R Zeiser","year":"2023","unstructured":"Zeiser R, et al. TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib\/II Stimulus-AML2 Study. Blood. 2023;142:59.","journal-title":"Blood"},{"issue":"2","key":"2133_CR71","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.1002\/ajh.27161","volume":"99","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024;99(2):E32\u20136.","journal-title":"Am J Hematol"},{"issue":"10","key":"2133_CR72","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1080\/21645515.2015.1056953","volume":"11","author":"L Cheng","year":"2015","unstructured":"Cheng L, Ruan Z. Tim-3 and Tim-4 as the potential targets for antitumor therapy. Hum Vaccin Immunother. 2015;11(10):2458\u201362.","journal-title":"Hum Vaccin Immunother"},{"key":"2133_CR73","doi-asserted-by":"publisher","first-page":"819790","DOI":"10.3389\/fonc.2022.819790","volume":"12","author":"MCM Kgokolo","year":"2022","unstructured":"Kgokolo MCM, et al. Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients. Front Oncol. 2022;12:819790.","journal-title":"Front Oncol"},{"issue":"162","key":"2133_CR74","first-page":"15","volume":"31","author":"F Chen","year":"2021","unstructured":"Chen F, et al. Prospects of TIM-3 as a Promising Diagnostic and Prognostic Biomarker for Cancer Patients. Discov Med. 2021;31(162):15\u201320.","journal-title":"Discov Med"},{"key":"2133_CR75","doi-asserted-by":"crossref","unstructured":"Hong J et al. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes. Front Oncol, 2022. Volume 12\u20132022.","DOI":"10.3389\/fonc.2022.879471"},{"issue":"1","key":"2133_CR76","doi-asserted-by":"publisher","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","volume":"2","author":"S Schwartz","year":"2022","unstructured":"Schwartz S, et al. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunother Adv. 2022;2(1):ltac019.","journal-title":"Immunother Adv"},{"issue":"2","key":"2133_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1\u2013positive B-cell lymphoma. Clin Cancer Res. 2021;27(2):473\u201384.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2133_CR78","doi-asserted-by":"publisher","first-page":"e003176","DOI":"10.1136\/jitc-2021-003176","volume":"9","author":"S Zhao","year":"2021","unstructured":"Zhao S, et al. Switch receptor T3\/28 improves long-term persistence and antitumor efficacy of CAR-T cells. J Immunother Cancer. 2021;9(12):e003176.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2133_CR79","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76(6):1578\u201390.","journal-title":"Cancer Res"},{"key":"2133_CR80","doi-asserted-by":"crossref","unstructured":"Blaeschke F et al. Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function. Front Immunol, 2022. Volume 13\u20132022.","DOI":"10.3389\/fimmu.2022.845499"},{"issue":"9","key":"2133_CR81","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"WS Lee","year":"2021","unstructured":"Lee WS, et al. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Mol Cancer Ther. 2021;20(9):1702\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2133_CR82","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713\u201323.","journal-title":"Blood"},{"key":"2133_CR83","doi-asserted-by":"publisher","first-page":"viii360","DOI":"10.1093\/annonc\/mdy286.004","volume":"29","author":"KH Lee","year":"2018","unstructured":"Lee KH, et al. CD13 and CD33 CAR-T cells for the treatment of myeloid malignancies. Ann Oncol. 2018;29:viii360\u20131.","journal-title":"Ann Oncol"},{"issue":"1","key":"2133_CR84","doi-asserted-by":"publisher","first-page":"2458843","DOI":"10.1080\/2162402X.2025.2458843","volume":"14","author":"X Zhang","year":"2025","unstructured":"Zhang X, et al. Dual nanobody-redirected and Bi-specific CD13\/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs. Oncoimmunology. 2025;14(1):2458843.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2133_CR85","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer. 2024;23(1):56.","journal-title":"Mol Cancer"},{"key":"2133_CR86","doi-asserted-by":"publisher","first-page":"1738558","DOI":"10.3389\/fphar.2025.1738558","volume":"16","author":"VA Cianga","year":"2025","unstructured":"Cianga VA, et al. Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy. Front Pharmacol. 2025;16:1738558.","journal-title":"Front Pharmacol"},{"issue":"9","key":"2133_CR87","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00262-025-04106-z","volume":"74","author":"S Li","year":"2025","unstructured":"Li S, et al. Precision sniper for solid tumors: CAR-NK cell therapy. Cancer Immunol Immunother. 2025;74(9):275.","journal-title":"Cancer Immunol Immunother"},{"key":"2133_CR88","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fimmu.2024.1407992","volume":"15","author":"AM Alviano","year":"2024","unstructured":"Alviano AM, et al. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies. Front Immunol. 2024;15:2024.","journal-title":"Front Immunol"},{"issue":"1","key":"2133_CR89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-024-10227-1","volume":"44","author":"AW Rankin","year":"2024","unstructured":"Rankin AW, et al. Evolving strategies for addressing CAR T-cell toxicities. Cancer Metastasis Rev. 2024;44(1):17.","journal-title":"Cancer Metastasis Rev"},{"key":"2133_CR90","doi-asserted-by":"crossref","unstructured":"Yu T, et al. Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma. Cancer Biology & Medicine; 2025. p. 20240538.","DOI":"10.20892\/j.issn.2095-3941.2024.0538"},{"issue":"1","key":"2133_CR91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40164-024-00534-2","volume":"13","author":"P Klaihmon","year":"2024","unstructured":"Klaihmon P, et al. Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion. Exp Hematol Oncol. 2024;13(1):67.","journal-title":"Exp Hematol Oncol"},{"key":"2133_CR92","doi-asserted-by":"publisher","first-page":"117388","DOI":"10.1016\/j.biopha.2024.117388","volume":"179","author":"KCS Pe","year":"2024","unstructured":"Pe KCS, et al. Optimization of anti-TIM3 chimeric antigen receptor with CD8\u03b1 spacer and TNFR-based costimulation for enhanced efficacy in AML therapy. Biomed Pharmacother. 2024;179:117388.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2133_CR93","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","volume":"10","author":"Y Lv","year":"2023","unstructured":"Lv Y, et al. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis. 2023;10(6):2366\u201382.","journal-title":"Genes Dis"},{"issue":"Supplement 1","key":"2133_CR94","doi-asserted-by":"publisher","first-page":"8837","DOI":"10.1182\/blood-2022-169811","volume":"140","author":"CJ Henry","year":"2022","unstructured":"Henry CJ, Lee M, Filipovic A. Lyt-200, a Humanized Anti-Galectin-9 Antibody, Exhibits Preclinical Efficacy in Models of Hematological Malignancies. Blood. 2022;140(Supplement 1):8837\u20138837.","journal-title":"Blood"},{"key":"2133_CR95","unstructured":"Sabatos-Peyton C. MBG453: A high affinity, ligand-blocking anti-TIM-3 monoclonal Ab. in American Association for Cancer Research (AACR) Annual Meeting. 2016."},{"issue":"13","key":"2133_CR96","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano G, et al. Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021;27(13):3620\u20139.","journal-title":"Clin Cancer Res"},{"key":"2133_CR97","unstructured":"A Phase Ib\/II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual. Disease After Allogeneic Stem Cell Transplantation. 2020."},{"issue":"9","key":"2133_CR98","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2217\/fon-2022-1237","volume":"19","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, et al. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncol. 2023;19(9):631\u201342.","journal-title":"Future Oncol"},{"key":"2133_CR99","doi-asserted-by":"crossref","unstructured":"Lin H, et al. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies. Volume 178. Biomedicine & Pharmacotherapy; 2024. p. 117252.","DOI":"10.1016\/j.biopha.2024.117252"},{"issue":"2","key":"2133_CR100","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra A, et al. Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Eur J Haematol. 2024;112(2):211\u201322.","journal-title":"Eur J Haematol"},{"issue":"10","key":"2133_CR101","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1111\/cas.15497","volume":"113","author":"J Nagasaki","year":"2022","unstructured":"Nagasaki J, Ishino T, Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci. 2022;113(10):3303\u201312.","journal-title":"Cancer Sci"},{"issue":"26","key":"2133_CR102","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood.2023019961","volume":"143","author":"J Vadakekolathu","year":"2024","unstructured":"Vadakekolathu J, Rutella S. Escape from T-cell\u2013targeting immunotherapies in acute myeloid leukemia. Blood. 2024;143(26):2689\u2013700.","journal-title":"Blood"},{"key":"2133_CR103","doi-asserted-by":"crossref","unstructured":"Batar P, et al. Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary. Pathology and Oncology Research; 2024. pp. 30\u20132024.","DOI":"10.3389\/pore.2024.1611497"},{"issue":"1","key":"2133_CR104","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24(1):20.","journal-title":"Mol Cancer"},{"key":"2133_CR105","doi-asserted-by":"crossref","unstructured":"van der Geest D et al. Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better? J Immunother Cancer, 2025. 13(11). p.e013110.","DOI":"10.1136\/jitc-2025-013110"},{"issue":"16","key":"2133_CR106","doi-asserted-by":"publisher","first-page":"7998","DOI":"10.3390\/ijms26167998","volume":"26","author":"AI Karkempetzaki","year":"2025","unstructured":"Karkempetzaki AI, Schatton T, Barthel SR. Galectin-9\u2014An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy. Int J Mol Sci. 2025;26(16):7998.","journal-title":"Int J Mol Sci"},{"key":"2133_CR107","doi-asserted-by":"crossref","unstructured":"B\u00e9ziat V, Casanova J-L. Monogenic disorders of immunity: Common variants are not so rare. Cell Genomics, 2026. 6(1). 1-20","DOI":"10.1016\/j.xgen.2025.101129"},{"key":"2133_CR108","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"W-H Lee","year":"2021","unstructured":"Lee W-H, et al. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Mol Cancer Ther. 2021;20:1702\u201312.","journal-title":"Mol Cancer Ther"},{"key":"2133_CR109","doi-asserted-by":"crossref","unstructured":"Guo X et al. Advances in the study of TIM3 in myelodysplastic syndrome. Front Immunol, 2025. Volume 16\u20132025.","DOI":"10.3389\/fimmu.2025.1647401"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02133-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:02:22Z","timestamp":1775203342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02133-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02133-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"216"}}